METTL3 and neoplasm: Multiple tumor models demonstrate a consistent writer–reader route in which METTL3/14 installs m6A on PD-L1 (CD274) transcripts and IGF2BP readers stabilize the mRNA, raising PD-L1 on the tumor surface and dampening cytotoxic T-cell activity; genetic or pharmacologic disruption of these nodes lowers PD-L1 and improves antitumor responses in vivo.